Electrophysiological effects of carvedilol administration in patients with dilated cardiomyopathy

Cardiovascular Drugs and Therapy

Volumn 22, Issue 3, 2008, Pages 169-176

  Kanoupakis, Emmanuel M ^a   Manios, Emmanuel G ^a   Mavrakis, Hercules E ^a   Kallergis, Eleftherios M ^a   Lyrarakis, George M ^a   Koutalas, Emmanuel P ^a   Vardas, Panos E ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Arrhythmias; Carvedilol; Dilated cardiomyopathy; Refractoriness

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO;

ADULT; AGED; ARRHYTHMOGENESIS; ARTICLE; ATRIOVENTRICULAR CONDUCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REFRACTORY PERIOD; HUMAN; HYPOTENSION; MALE; POTASSIUM CURRENT; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RR INTERVAL;

ACTION POTENTIALS; ADRENERGIC BETA-ANTAGONISTS; AGED; BLOOD PRESSURE; CARBAZOLES; CARDIOMYOPATHY, DILATED; CARDIOTONIC AGENTS; DEATH, SUDDEN, CARDIAC; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPANOLAMINES; REFRACTORY PERIOD, ELECTROPHYSIOLOGICAL; RISK; SINOATRIAL NODE; STROKE VOLUME; TACHYCARDIA, VENTRICULAR; VENTRICULAR FUNCTION, LEFT; VENTRICULAR FUNCTION, RIGHT;

EID: 48349098218     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-008-6081-3     Document Type: Article

References (32)

1. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-55.
2. Packer M, Fowler MB, Roecker EB, et al. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group: Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation 2002;106:2194-9.
3. McMurray J, Køber L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction. Results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) Trial. J Am Coll Cardiol 2005;45:525-30.
4. Senior R, Muller-Beckmann B, DasGupta P, van der DR, Lahiri A. Effects of carvedilol on ventricular arrhythmias. J Cardiovasc Pharmacol 1992;19:S117-21.
5. Cice G, Tagliamonte E, Ferrara L, Lacono A. Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: Double-blind, randomized, placebo-controlled study. Eur Heart J 2000;21:1259-64.
6. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996;94:2793-9.
7. Katritsis DG, Panagiotakos DB, Karvouni E, et al. Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. Am J Cardiol 2003;92:1116-9.
8. Kanoupakis EM, Manios EG, Mavrakis HE, Tzerakis PG, Mouloudi HK, Vardas PE. Comparative effects of carvedilol and amiodarone on conversion and recurrence rates of persistent atrial fibrillation. Am J Cardiol 2004;94:659-62.
9. 2+ current in rabbit ventricular myocytes. Eur J Pharmacol 1999;376:189-201.
10. Karle CA, Kreye VA, Thomas D, et al. Antiarrhythmic drug carvedilol inhibits HERG potassium channels. Cardiovasc Res 2001;49:361-70.
11. i in ventricular myocytes compared with those of timolol and atenolol. Circ J 2003;67:83-90.
12. Book WM. Carvedilol. A nonselective beta blocking agent with antioxidant properties. Congest Heart Fail 2002;8:173-7, 190.
13. Josephson M. Clinical cardiac electrophysiology: techniques and interpretations. 2nd ed. Philadelphia: Lea & Febiger; 1993. p. 22-70.
14. Franz MR. Method and theory of monophasic action potential recording. Prog Cardiovasc Dis 1991;33:347-68.
15. Karjalainen J, Viitasalo M, Manttari M, Manninen V. Relation between QT intervals and heart rates from 40 to 120 beats/min in rest electrocardiograms of men and a simple method to adjust QT interval values. J Am Coll Cardiol 1994;23:1547-53.
16. Kodama I, Suzuki R, Kamiya K, Iwata H, Toyama J. Effects of long-term oral administration of amiodarone on the electromechanical performance of rabbit ventricular muscle. Br J Pharmacol 1992;107:502-9.
17. Sager PT, Uppal P, Follmer C, Antimisiaris M, Pruitt C, Singh BN. Frequency-dependent electrophysiologic effects of amiodarone in humans. Circulation 1993;88:1063-71.
18. Amiodarone Trials Meta-Analysis Investigators. Effects of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure. Lancet 1997;350:1417-24.
19. Luo CH, Rudy Y. A model of the ventricular cardiac action potential. Depolarization, repolarization, and their interaction. Circ Res 1991;68:1501-26.
20. Davidenko JM, Antzelevitch C. Electrophysiological mechanisms underlying rate-dependent changes of refractoriness in normal and segmentally depressed canine Purkinje fibers. The characteristics of post-repolarization refractoriness. Circ Res 1986;58:257-68.
21. Fesmire SI, Marcoux LG, Lyyski DS, Sprague MK, Kennedy HL, Eichhorn EJ. Effects of selective versus nonselective beta blockade on QT dispersion in patients with nonischemic dilated cardiomyopathy. Am J Cardiol 1999;84:350-4.
22. Piccirillo G, Quaglione R, Nocco M, et al. Effects of long-term betablocker (metoprolol or carvedilol) therapy on QT variability in subjects with chronic heart failure secondary to ischemic cardiomyopathy. Am J Cardiol 2002;90:1113-7.
23. Yildirir A, Sade E, Tokgozoglu L, Oto A. the effects of chronic carvedilol therapy on QT dispersion in patients with congestive heart failure. Eur H Heart Fail 2001;3:717-21.
24. Chiamvimonvat N, Kargacin ME, Clark RB, Duff HJ. Effects of intracellular calcium on sodium current density in cultured neonatal rat cardiac myocytes. J Physiol 1995;483:307-18.
25. Maltsev VA, Sabbab HN, Undrovinas AI. Down-regulation of sodium current in chronic heart failure: Effect of long-term therapy with carvedilol. Cell Mol Life Sci 2002;59:1561-8.
26. Costard-Jaeckle A, Franz MR. Frequency-dependent antiarrhythmic drug effects on postrepolarization refractoriness and ventricular conduction time in canine ventricular myocardium in vivo. J Pharmacol Exp Ther 1989;251:39-46.
27. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 2003;42:1944-51.
28. Moe GK. On the multiple wavelet hypothesis of atrial fibrillation. Arch Int Pharmacodyn Ther 1962;140:183-8.
29. Allessie MA, Lammers WJEP, Rensma PL, Bonke FIM. Flutter and fibrillation in experimental modes: what has been learned that can be applied to humans. In: Brugada P, Wellens HJJ, editors. Cardiac arrhythmias: where to go from here. Mount Kisco: Futura; 1987. p. 67-82.
30. Konings KTS, Kirchhof CJ, Smeets JR, Wellens HJ, Penn OC, Allessie MA. High density mapping of electrically induced atrial fibrillation in man. Circulation 1994;89:1665-80.
31. Horio T, Ito S, Aoyama M, Takeda Y, et al. Effect of carvedilol on atrioventricular conduction in the ischemic heart. Eur J Pharmacol 2001;4:145-53.
32. Nagele H, Bohlmann M, Eck U, Petersen B, Rodiger W. Combination therapy with carvedilol and amiodarone in patients with severe heart failure. Eur J Heart Fail 2000;2:71-9.